N. P. Gould

TL;DR: A series of 3-substituted 5-phenyl-1,4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin, serve to illuminate the distinction between central and peripheral CCK receptors, as well as to provide orally effective CCK antagonists of potential pharmacological or therapeutic utility.

TL;DR: The first nonpeptide antagonists of the neurohypophyseal hormone, oxytocin (OT) are described, including L-366,509, an orally bioavailable OT antagonist with good in vivo duration.

TL;DR: The synthesis of a series of [(2,3,9,9a-tetrahydro-3-oxo- 9a-substituted-1H-fluoren-7-yl)oxy]alk anoic acids and their analogues is described, which demonstrated the marked stereospecificity of the most active compounds.

TL;DR: A clinical advantage is suggested for the nondiuretic (aryloxy)alkanoic acids which possess in vitro and in vivo activities in the cat brain assays that are comparable or superior to dually active compounds.

TL;DR: The high reactivity of Fmoc-L-pipecolic acid chloride used in the di- to tripeptide step averted diketopiperazine formation seen with active ester couplings and provided a rapid method for assembly of the linear hexapeptide.